Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data

Hematol Oncol. 2019 Oct;37(4):490-492. doi: 10.1002/hon.2645. Epub 2019 Jul 24.

Authors

Affiliations

¹ Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
² Radiology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.
³ PathologyDepartment, G. Papanicolaou Hospital, Thessaloniki, Greece.

PMID: 31339579
DOI: 10.1002/hon.2645

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Allografts
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Brentuximab Vedotin
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease / mortality*
Hodgkin Disease / therapy*
Humans
Immunoconjugates / administration & dosage
Male
Middle Aged
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Retrospective Studies
Survival Rate

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Brentuximab Vedotin